Verrica’s YCANTH Posts Record Sales, But Mid-2027 Warts Data Represents The Key Value Inflection Point

Verrica Reports Strong YCANTH Demand, Advances Pipeline, and Extends Cash Runway

Verrica Pharmaceuticals announced its second quarter 2026 financial results, reporting record demand for YCANTH® (VP-102) with 19,626 dispensed applicator units, representing a 28.3% sequential and 46.1% year-over-year increase. Total revenue for the quarter reached $5.9 million, including $5.1 million in U.S. YCANTH net product revenue. The company provided updates on its global Phase 3 program for YCANTH in common warts, with topline data expected in mid-2027, and progress for VP-315 in basal cell carcinoma. A new $27.5 million credit facility is anticipated to extend the company's cash runway into 2028, supporting continued commercialization and pipeline advancement.

• Verrica Pharmaceuticals achieved strong commercial performance for its flagship product, YCANTH® (VP-102), in Q2 2026. The company reported a record 19,626 dispensed applicator units, marking a significant 46.1% increase year-over-year. This robust demand contributed to a U.S. YCANTH net product revenue of $5.1 million and a total revenue of $5.9 million for the quarter.
• The company is actively advancing its clinical pipeline, particularly with YCANTH® (VP-102) in a global Phase 3 program for common warts. This indication is estimated to affect three times more patients than molluscum. Enrollment is progressing well in the COVE-2 study, and the first patients in the U.S. and Japan were dosed in the second pivotal trial, COVE-3, with topline data anticipated in mid-2027.
• Verrica has strategically strengthened its financial position by securing a new credit facility of up to $27.5 million, which is projected to extend its cash runway into 2028. This non-dilutive capital will support YCANTH's continued commercialization and the advancement of its Phase 3 common warts program. Additionally, the company remains encouraged by Phase 2 data for its novel oncolytic peptide, VP-315, showing potential abscopal effects in basal cell carcinoma, positioning it as a Phase 3-ready asset.

YCANTH's Global Phase 3 Program for Common Warts Unveiled

Beyond its established use in molluscum contagiosum, VP-102 (cantharidin 0.7% w/v, delivered via a single-use, shelf-stable applicator) is also being evaluated for the treatment of external genital warts caused by human papilloma virus. This investigation was conducted as a randomized, double-blind, vehicle-controlled phase II clinical trial (NCT03981822), which ran from an actual study start date of June 25, 2019, through an actual completion date of July 8, 2020, with primary completion reached on May 21, 2020.

The trial employed a two-part intervention model. Part A served as a dose-finding stage, from which 6-hour and 24-hour VP-102 regimens under occlusion were selected for further evaluation. Part B then assessed the safety and efficacy of these two selected regimens against vehicle control. Pooled results from Parts A and B demonstrated that 36.7% of participants in the 6-hour regimen and 33.3% in the 24-hour regimen achieved complete clearance of all treatable external genital warts at the end of treatment, compared with only 4.2% (p < 0.0048) and 0% (p < 0.0075) in the respective vehicle arms.

Taken together, the adverse event profile and efficacy data for both occlusion regimens support an acceptable risk-benefit balance, providing the rationale for advancing to a larger, vehicle-controlled phase III study in external genital warts. This positions VP-102 as a candidate therapy extending beyond molluscum contagiosum into a second dermatologic viral wart indication with a defined, occlusion-based dosing strategy.

YCANTH's Efficacy and Impact in Molluscum Contagiosum

Recent clinical data highlights the efficacy of newly approved topical agents for molluscum contagiosum. In the B-SIMPLE4 Phase III trial for berdazimer gel 10.3%, nearly 40% of patients achieved complete lesion clearance by week 12, compared to 20% in the vehicle group. Furthermore, a substantial majority of participants in the berdazimer arm reported their lesions as "very much improved" or "much improved" (82% by patient report, 80% by investigator assessment), significantly higher than the vehicle group. Patient experience data underscores the clinical meaningfulness of these outcomes; even among those with less than complete clearance, a majority found the reduction in lesion count to be meaningful, with high overall satisfaction rates reported. A 2025 analysis also highlighted promising efficacy for another new agent, VP-102 (cantharidin 0.7%), noting that such in-office topicals may enhance efficacy by overcoming adherence challenges associated with daily home-administered medications.

Beyond daily topical therapies, a range of procedural and intralesional immunotherapies demonstrate high response rates. A 2026 systematic review of 89 studies found that curettage achieved the highest clearance rate at 97.8%. Other effective modalities included autoinoculation (79.4% clearance), podophyllotoxin (75.0%), and potassium hydroxide (KOH) (73.8%), all with minimal local side effects. A head-to-head trial from 2017 found no statistically significant difference in efficacy between 10% KOH solution (80% clearance) and weekly cryotherapy (83.3% clearance) over a six-week period. Cryotherapy and laser therapies offer rapid resolution but are associated with greater discomfort and cost.

Intralesional immunotherapies have emerged as effective options, particularly for persistent or recurring cases. A 2021 retrospective analysis of intralesional measles, mumps, and rubella (MMR) vaccine reported an 81.8% complete clearance rate at 12 weeks with no significant adverse effects. A subsequent 2024 study comparing intralesional antigens confirmed these findings, demonstrating complete clearance in 80% of patients treated with MMR and 73.3% of those treated with tuberculin (PPD) antigen, compared to no response in the majority of the saline control group. This body of evidence indicates that while multiple effective treatments exist, the optimal management strategy requires an individualized approach that balances efficacy, safety, patient age, and immune status.

Navigating Current Treatment Challenges in Molluscum Contagiosum

Despite the availability of multiple therapeutic modalities for Molluscum contagiosum (MC), no gold-standard treatment or clinical consensus has been established. Current approaches—ranging from procedural interventions like curettage and electrodessication to topical agents—are hampered by high failure rates, adherence issues, and a persistent lack of robust comparative data.

• Absence of standardized treatment protocols: No consensus exists regarding optimal therapy, and comparative efficacy and safety data remain limited despite the range of available modalities, complicating evidence-based decision-making.

• High treatment failure rates with curettage: In a study of 73 patients, curettage was associated with treatment failure in 66% (42/64) at week 4 and 45% (25/55) at week 8. Key risk factors included lesion count at baseline (P < 0.001), number of anatomical sites involved (P < 0.001), and concomitant atopic dermatitis (P = 0.038 at week 4; P < 0.001 at week 8), with lesion number identified as the primary driver of failure—highlighting the need for alternative options in patients with extensive disease.

• Poor adherence to topical therapies: Despite favorable safety profiles, painless administration, and suitability for pediatric and home use, individual topical treatments suffer from poor patient adherence. This is largely attributed to delayed onset of action, prolonged treatment duration, and uncertain perceived benefit, all of which undermine real-world efficacy.

• Limited data on emerging topical agents: Newer agents such as VP-102 (cantharidin 0.7% drug-device combination) and SB206 (berdazimer gel 10.3%) have demonstrated promising efficacy in clinical trials; however, whether they meaningfully improve adherence compared to older topicals remains unclear. In-office application of agents like cantharidin may help circumvent nonadherence issues associated with daily home-administered regimens.

• Specific agent limitations: Cidofovir gel (1%), while showing utility in select HIV-positive patients with extensive, confluent MC, is associated with significant local inflammation, inconsistent tolerability, and disappointing results in related papillomavirus lesions and acyclovir-resistant herpes ulcerations.

• Recurrence remains a persistent issue: Both curettage and electrodessication are associated with substantial recurrence rates (49.2% and 35%, respectively), underscoring the lack of durable clearance with current procedural approaches.

• Anatomically challenging presentations: Periocular MC poses distinct diagnostic and therapeutic difficulties, particularly when lesions are isolated, given the proximity to the eyeball and the need for differential diagnosis.

• Insufficient clinical evidence base: Across both topical and procedural treatments, there is a notable shortage of large, well-designed trials—particularly ones that account for adherence—needed to establish evidence-based treatment recommendations and optimize long-term outcomes.

• Need for individualized management: Given the variability in efficacy, safety, and recurrence across modalities, treatment selection must be tailored to patient-specific factors such as age, lesion severity, and immune status, rather than following a one-size-fits-all approach.

YCANTH's Momentum Fuels Broader Dermatologic Ambitions

Verrica Pharmaceuticals' recent financial results paint a picture of a company building significant momentum, primarily driven by the impressive demand for YCANTH® (VP-102) in molluscum contagiosum. This strong commercial performance is more than just a revenue boost; it validates the market's appetite for a standardized, proprietary cantharidin formulation, especially given the historical reliance on compounded versions and the lack of FDA-approved options for many common dermatological conditions. The success of YCANTH provides a robust platform for the company's ambitious pipeline.

The strategic move to advance VP-102 into a global Phase 3 program for common warts is particularly noteworthy. Warts represent a vast, underserved market, and securing the first FDA-approved treatment could be a significant win. However, the path is not without its challenges. While cantharidin has a long history of use for warts, studies indicate that its efficacy can vary, and it may not always outperform established conventional therapies. Furthermore, the inherent vesicant action of cantharidin means local skin reactions like blistering and pain are expected, which could influence patient and physician acceptance, especially in a competitive treatment landscape.

Beyond YCANTH, the progress of VP-315, an oncolytic peptide for basal cell carcinoma, signals a strategic diversification into oncology. This asset, with its distinct immunotherapeutic mechanism, could open new avenues for growth and address different unmet needs. The newly secured credit facility is a critical enabler, providing the financial runway necessary to sustain YCANTH's commercial growth and advance these key pipeline assets, positioning Verrica to potentially reshape treatment paradigms across several dermatological and dermato-oncological conditions.